FDA to Address Female Sexual Enhancement Drugs

LOS ANGELES — The topic of female sexual dysfunction — and drugs to treat it — will be front and center at an FDA meeting this month, one in a series of 20 looking at “patient-focused drug development.”

Critics have accused the Food and Drug Administration of having a gender bias, pointing out that it has approved six male-targeted drugs to help them overcome anxiety, physiology and more to get an erection, but has yet to approve a single female equivalent. 

The meeting to be held Oct. 27-28 will include statements from patients about the impact that female sexual dysfunction has had on their lives, WebMD reports. It will also include a scientific workshop to discuss how to diagnose the disorder and measure how well medications for it work.

Advocating for pharmaceutical gender inclusivity is Even the Score, a campaign that launched in June and is backed by the drug companies of at least three potential treatments for female sexual dysfunction.

A petition to the FDA posted by Even the Score on Change.org attracted more than 16,000 signatures. The petition addresses the FDA: “We urge you to work fairly and urgently toward a solution to an unmet medical need…”

Others, including the National Women’s Health Network and the American Medical Women’s Association, believe that the dearth of pharmaceutical options for women is not a gender bias, but a reflection of how much more complicated treating female sexual dysfunction can be.  

Following, they have supported the FDA’s decisions not to approve a drug for female sexual dysfunction, arguing that women may need more than a single pill to boost their libido. Viagra and Cialis target one important aspect of sex — the erection — but do not address psychological aspects of arousal, which may be key for women’s satisfaction,

Cindy Pearson, executive director of the National Women’s Health Network, says while the FDA has not been immune to gender bias, she doesn’t believe that is what’s delaying the drugs. “If it were gender bias, we would be yelling and screaming,” Pearson said. “The problem is the drugs. Our biology is so much more complicated than men’s.”

Related:  

Copyright © 2025 Adnet Media. All Rights Reserved. XBIZ is a trademark of Adnet Media.
Reproduction in whole or in part in any form or medium without express written permission is prohibited.

More News

Fleshlight Debuts Ebony Mystique Stroker

Fleshlight has introduced its new Ebony Mystique Pro stroker, Goddess Land.

Sigafun Debuts AI Sex Doll

Pleasure brand Sigafun has introduced its first AI model to its Hybrid Series of sex dolls.

Lifelong Merchant Services Adds New Team Members

Point of Sale (POS) provider Lifelong Merchant Services has added industry veterans Megan Abbatelli and Cam Jennings to its team.

Male Power Adds 'Spartacus' to 'Fetish' Collection

Male Power has introduced the new Spartacus design to its Fetish collection.

Orion Introduces New Vibrator From 'Javida' Line

Orion Wholesale has debuted the new 4-Function Vibrator from its Javida line.

Momentum Management Launches 'Dynamo Wellness' Brand

Momentum Management has launched its new Dynamo Wellness brand.

Adam & Eve Reveals Results of 'Sex Dream' Survey

Adam & Eve has released the results of a survey asking respondents if they have ever had a sex dream.

Tenga Debuts New 'Spinner DX' Strokers

Pleasure brand Tenga has introduced its new Spinner DX stroker sleeves.

Honey Play Box Receives EU Patent Approval for Tapping Technology

Honey Play Box has received E.U. patent approval for its tapping technology.

Carly S. Relaunches HornyStoner.com

Sexpert Carly S. has relaunched her online store HornyStoner.com.

Show More